v3.26.1
Segment information - Schedule of Segment Financial Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting Information [Line Items]    
Total revenue $ 106,677 $ 93,881
Cost of revenue from sale of therapies (434) (831)
R&D expenses (61,113) (56,468)
SG&A expenses (37,850) (40,198)
Net income 12,971 5,023
Reportable segment    
Segment Reporting Information [Line Items]    
Total revenue 106,677 93,881
Cost of revenue from sale of therapies (434) (831)
Other segment (expense) income, net (6,185) (6,163)
Net income 12,971 5,023
Reportable segment | External R&D    
Segment Reporting Information [Line Items]    
R&D expenses (38,792) (37,931)
Reportable segment | PRAME programs | External R&D    
Segment Reporting Information [Line Items]    
R&D expenses (21,214) (17,305)
Reportable segment | Tebentafusp programs | External R&D    
Segment Reporting Information [Line Items]    
R&D expenses (8,239) (7,990)
Reportable segment | Infectious disease programs | External R&D    
Segment Reporting Information [Line Items]    
R&D expenses (846) (1,405)
Reportable segment | All other external clinical and preclinical costs | External R&D    
Segment Reporting Information [Line Items]    
R&D expenses (8,493) (11,231)
Reportable segment | Salaries and other employee related cost    
Segment Reporting Information [Line Items]    
R&D expenses (14,140) (11,043)
SG&A expenses (13,090) (12,218)
Reportable segment | Other SG&A expenses    
Segment Reporting Information [Line Items]    
SG&A expenses $ (21,065) $ (20,672)